SGLT2 inhibitors as a therapeutic option for diabetic nephropathy

International Journal of Molecular Sciences

Volumn 18, Issue 5, 2017, Pages

  Kawanami, Daiji ^a   Matoba, Keiichiro ^a   Takeda, Yusuke ^a   Nagai, Yosuke ^a   Akamine, Tomoyo ^a,b   Yokota, Tamotsu ^a   Sango, Kazunori ^b   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Cardiovascular disease; Diabetic nephropathy; SGLT2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LUSEOGLIFLOZIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; TRANSFORMING GROWTH FACTOR BETA; URIC ACID; SODIUM GLUCOSE COTRANSPORTER 2;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DIABETIC PATIENT; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ULTRAFILTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; COMPLICATION; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; PHLORHIZIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85019948018     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18051083     Document Type: Review

References (76)

1. De Nicola, L.; Gabbai, F.B.; Liberti, M.E.; Sagliocca, A.; Conte, G.; Minutolo, R, Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: Targeting the renal tubule in diabetes. Am. J. Kidney Dis. 2014, 64, 16–24. [CrossRef] [PubMed]
2. Stratton, I.M.; Adler, A.I.; Neil, H.A.; Matthews, D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C.; Holman, R.R, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000, 321, 405–412. [CrossRef] [PubMed]
3. Wong, M.G.; Perkovic, V.; Chalmers, J.; Woodward, M.; Li, Q.; Cooper, M.E.; Hamet, P.; Harrap, S.; Heller, S.; MacMahon, S.; et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016, 39, 694–700. [CrossRef] [PubMed]
4. Goto, A.; Arah, O.A.; Goto, M.; Terauchi, Y.; Noda, M, Severe hypoglycaemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis. BMJ 2013, 347, f4533. [CrossRef] [PubMed]
5. Abdul-Ghani, M.A.; DeFronzo, R.A, Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. J. Intern. Med. 2014, 276, 352–363. [CrossRef] [PubMed]
6. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015, 373, 2117–2128. [CrossRef] [PubMed]
7. Wanner, C.; Inzucchi, S.E.; Lachin, J.M.; Fitchett, D.; von Eynatten, M.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Zinman, B.; et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 2016, 375, 323–334. [CrossRef] [PubMed]
8. Kawanami, D.; Matoba, K.; Utsunomiya, K, Signaling pathways in diabetic nephropathy. Histol. Histopathol. 2016, 31, 1059–1067. [PubMed]
9. Kawanami, D.; Matoba, K.; Sango, K.; Utsunomiya, K, Incretin-based therapies for diabetic complications: Basic mechanisms and clinical evidence. Int. J. Mol. Sci. 2016, 17, 1223. [CrossRef] [PubMed]
10. Abdul-Ghani, M.A.; Norton, L.; DeFronzo, R.A, Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am. J. Physiol. Ren. Physiol. 2015, 309, F889–F900. [CrossRef] [PubMed]
11. Zanoli, L.; Granata, A.; Lentini, P.; Rastelli, S.; Fatuzzo, P.; Rapisarda, F.; Castellino, P, Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Sci. World J. 2015, 2015, 317507. [CrossRef] [PubMed]
12. Vrhovac, I.; Balen Eror, D.; Klessen, D.; Burger, C.; Breljak, D.; Kraus, O.; Radovic, N.; Jadrijevic, S.; Aleksic, I.; Walles, T., et al. Localizations of Na+-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflug. Arch. 2015, 467, 1881–1898. [CrossRef] [PubMed]
13. Wright, E.M.; Loo, D.D.; Hirayama, B.A, Biology of human sodium glucose transporters. Physiol. Rev. 2011, 91, 733–794. [CrossRef] [PubMed]
14. Farber, S.J.; Berger, E.Y.; Earle, D.P, Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J. Clin. Investig. 1951, 30, 125–129. [CrossRef] [PubMed]
15. Abdul-Ghani, M.A.; Norton, L.; Defronzo, R.A, Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr. Rev. 2011, 32, 515–531. [CrossRef] [PubMed]
16. DeFronzo, R.A.; Norton, L.; Abdul-Ghani, M, Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 2017, 13, 11–26. [CrossRef] [PubMed]
17. Mogensen, C.E, Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Investig. 1971, 28, 101–109. [CrossRef] [PubMed]
18. Novikov, A.; Vallon, V, Sodium glucose cotransporter 2 inhibition in the diabetic kidney: An update. Curr. Opin. Nephrol. Hypertens. 2016, 25, 50–58. [CrossRef] [PubMed]
19. Vallon, V.; Gerasimova, M.; Rose, M.A.; Masuda, T.; Satriano, J.; Mayoux, E.; Koepsell, H.; Thomson, S.C.; Rieg, T, SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am. J. Physiol. Ren. Physiol. 2014, 306, F194–F204. [CrossRef] [PubMed]
20. Vallon, V.; Rose, M.; Gerasimova, M.; Satriano, J.; Platt, K.A.; Koepsell, H.; Cunard, R.; Sharma, K.; Thomson, S.C.; Rieg, T, Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am. J. Physiol. Ren. Physiol. 2013, 304, F156–F167. [CrossRef] [PubMed]
21. Arakawa, K.; Ishihara, T.; Oku, A.; Nawano, M.; Ueta, K.; Kitamura, K.; Matsumoto, M.; Saito, A, Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095. Br. J. Pharmacol. 2001, 132, 578–586. [CrossRef] [PubMed]
22. Rahmoune, H.; Thompson, P.W.; Ward, J.M.; Smith, C.D.; Hong, G.; Brown, J, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54, 3427–3434. [CrossRef] [PubMed]
23. Wang, X.X.; Levi, J.; Luo, Y.; Myakala, K.; Herman-Edelstein, M.; Qiu, L.; Wang, D.; Peng, Y.; Grenz, A.; Lucia, S.; et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipic accumulation, inflammation, and the development of nephropathy in diabetic mice. J. Biol. Chem. 2017, 292, 5335–5348. [CrossRef] [PubMed]
24. Vallon, V.; Thomson, S.C, Renal function in diabetic disease models: The tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 2012, 74, 351–375. [CrossRef] [PubMed]
25. Vallon, V.; Platt, K.A.; Cunard, R.; Schroth, J.; Whaley, J.; Thomson, S.C.; Koepsell, H.; Rieg, T, SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 2011, 22, 104–112. [CrossRef] [PubMed]
26. Rieg, T.; Masuda, T.; Gerasimova, M.; Mayoux, E.; Platt, K.; Powell, D.R.; Thomson, S.C.; Koepsell, H.; Vallon, V, Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am. J. Physiol. Ren. Physiol. 2014, 306, F188–F193. [CrossRef] [PubMed]
27. Vallon, V, The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 2015, 66, 255–270. [CrossRef] [PubMed]
28. Powell, D.R.; DaCosta, C.M.; Gay, J.; Ding, Z.M.; Smith, M.; Greer, J.; Doree, D.; Jeter-Jones, S.; Mseeh, F.; Rodriguez, L.A.; et al. Improved glycemic control in mice lacking Sglt1 and Sglt 2. Am. J. Physiol. Endocrinol. Metab. 2013, 304, E117–E130. [CrossRef] [PubMed]
29. Malatiali, S.; Francis, I.; Barac-Nieto, M, Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp. Diabetes Res. 2008, 2008, 305403. [CrossRef] [PubMed]
30. Osorio, H.; Coronel, I.; Arellano, A.; Pacheco, U.; Bautista, R.; Franco, M.; Escalante, B, Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid. Med. Cell. Longev. 2012, 2012, 542042. [CrossRef] [PubMed]
31. Gembardt, F.; Bartaun, C.; Jarzebska, N.; Mayoux, E.; Todorov, V.T.; Hohenstein, B.; Hugo, C, The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am. J. Physiol. Ren. Physiol. 2014, 307, F317–F325. [CrossRef] [PubMed]
32. Ojima, A.; Matsui, T.; Nishino, Y.; Nakamura, N.; Yamagishi, S, Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm. Metab. Res. 2015, 47, 686–692. [CrossRef] [PubMed]
33. Panchapakesan, U.; Pegg, K.; Gross, S.; Komala, M.G.; Mudaliar, H.; Forbes, J.; Pollock, C.; Mather, A, Effects of SGLT2 inhibition in human kidney proximal tubular cells—Renoprotection in diabetic nephropathy? PLoS ONE 2013, 8, e54442. [CrossRef] [PubMed]
34. Kojima, N.; Williams, J.M.; Takahashi, T.; Miyata, N.; Roman, R.J, Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J. Pharmacol. Exp. Ther. 2013, 345, 464–472. [CrossRef] [PubMed]
35. Terami, N.; Ogawa, D.; Tachibana, H.; Hatanaka, T.; Wada, J.; Nakatsuka, A.; Eguchi, J.; Horiguchi, C.S.; Nishii, N.; Yamada, H.; et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE 2014, 9, e100777. [CrossRef] [PubMed]
36. Hatanaka, T.; Ogawa, D.; Tachibana, H.; Eguchi, J.; Inoue, T.; Yamada, H.; Takei, K.; Makino, H.; Wada, J, Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol. Res. Perspect. 2016, 4, e00239. [CrossRef] [PubMed]
37. Nagata, T.; Fukuzawa, T.; Takeda, M.; Fukazawa, M.; Mori, T.; Nihei, T.; Honda, K.; Suzuki, Y.; Kawabe, Y, Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br. J. Pharmacol. 2013, 170, 519–531. [CrossRef] [PubMed]
38. Gangadharan Komala, M.; Gross, S.; Mudaliar, H.; Huang, C.; Pegg, K.; Mather, A.; Shen, S.; Pollock, C.A.; Panchapakesan, U, Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS ONE 2014, 9, e108994. [CrossRef] [PubMed]
39. Gallo, L.A.; Ward, M.S.; Fotheringham, A.K.; Zhuang, A.; Borg, D.J.; Flemming, N.B.; Harvie, B.M.; Kinneally, T.L.; Yeh, S.M.; McCarthy, D.A.; et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci. Rep. 2016, 6, 26428. [CrossRef] [PubMed]
40. Zhang, Y.; Thai, K.; Kepecs, D.M.; Gilbert, R.E, Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS ONE 2016, 11, e0144640. [CrossRef] [PubMed]
41. Ma, Q.; Steiger, S.; Anders, H.J, Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol. Rep. 2017, 5, e13228. [CrossRef] [PubMed]
42. Gilbert, R.E, Sodium-glucose linked transporter-2 inhibitors: Potential for renoprotection beyond blood glucose lowering? Kidney Int. 2014, 86, 693–700. [CrossRef] [PubMed]
43. Heerspink, H.J.; Desai, M.; Jardine, M.; Balis, D.; Meininger, G.; Perkovic, V, Canagliflozin slows progression of renal function decline independently of glycemic effects. J. Am. Soc. Nephrol. 2016, 28, 368–375. [CrossRef] [PubMed]
44. Neal, B.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Stein, P.; Desai, M.; Shaw, W.; Jiang, J.; Vercruysse, F.; et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial. Am. Heart J. 2013, 166, 217–223. [CrossRef] [PubMed]
45. Baker, W.L.; Smyth, L.R.; Riche, D.M.; Bourret, E.M.; Chamberlin, K.W.; White, W.B. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J. Am. Soc. Hypertens. 2014, 8, 262–275. [CrossRef] [PubMed]
46. Heerspink, H.J.; Perkins, B.A.; Fitchett, D.H.; Husain, M.; Cherney, D.Z, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016, 134, 752–772. [CrossRef] [PubMed]
47. Sjostrom, C.D.; Hashemi, M.; Sugg, J.; Ptaszynska, A.; Johnsson, E, Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes. Metab. 2015, 17, 809–812. [CrossRef] [PubMed]
48. Cefalu, W.T.; Stenlof, K.; Leiter, L.A.; Wilding, J.P.; Blonde, L.; Polidori, D.; Xie, J.; Sullivan, D.; Usiskin, K.; Canovatchel, W.; et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia 2015, 58, 1183–1187. [CrossRef] [PubMed]
49. Cherney, D.Z.; Perkins, B.A.; Soleymanlou, N.; Har, R.; Fagan, N.; Johansen, O.E.; Woerle, H.J.; von Eynatten, M.; Broedl, U.C, The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc. Diabetol. 2014, 13, 28. [CrossRef] [PubMed]
50. Chilton, R.; Tikkanen, I.; Cannon, C.P.; Crowe, S.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E, Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab. 2015, 17, 1180–1193. [CrossRef] [PubMed]
51. Anderson, S.; Brenner, B.M, Pathogenesis of diabetic glomerulopathy: Hemodynamic considerations. Diabetes Metab. Rev. 1988, 4, 163–177. [CrossRef] [PubMed]
52. Sochett, E.B.; Cherney, D.Z.; Curtis, J.R.; Dekker, M.G.; Scholey, J.W.; Miller, J.A, Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J. Am. Soc. Nephrol. 2006, 17, 1703–1709. [CrossRef] [PubMed]
53. Thomson, S.C.; Vallon, V.; Blantz, R.C, Kidney function in early diabetes: The tubular hypothesis of glomerular filtration. Am. J. Physiol. Ren. Physiol. 2004, 286, F8–F15. [CrossRef] [PubMed]
54. Cherney, D.Z.; Perkins, B.A.; Soleymanlou, N.; Maione, M.; Lai, V.; Lee, A.; Fagan, N.M.; Woerle, H.J.; Johansen, O.E.; Broedl, U.C.; et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014, 129, 587–597. [CrossRef] [PubMed]
55. Schnermann, J.; Levine, D.Z, Paracrine factors in tubuloglomerular feedback: Adenosine, ATP, and nitric oxide. Annu. Rev. Physiol. 2003, 65, 501–529. [CrossRef] [PubMed]
56. Skrtic, M.; Yang, G.K.; Perkins, B.A.; Soleymanlou, N.; Lytvyn, Y.; von Eynatten, M.; Woerle, H.J.; Johansen, O.E.; Broedl, U.C.; Hach, T.; et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014, 57, 2599–2602. [CrossRef] [PubMed]
57. Cherney, D.Z.; Miller, J.A.; Scholey, J.W.; Bradley, T.J.; Slorach, C.; Curtis, J.R.; Dekker, M.G.; Nasrallah, R.; Hebert, R.L.; Sochett, E.B, The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 2008, 57, 688–695. [CrossRef] [PubMed]
58. Ito, D.; Ikuma-Suwa, E.; Inoue, K.; Kaneko, K.; Yanagisawa, M.; Inukai, K.; Noda, M.; Shimada, A, Effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetes: An open-label study. J. Clin. Med. Res. 2017, 9, 154–162. [CrossRef] [PubMed]
59. Petrykiv, S.I.; Laverman, G.D.; Zeeuw, D.; Heerspink, H.J, The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients. Diabetes Obes. Metab. 2017. [CrossRef] [PubMed]
60. Lambers Heerspink, H.J.; de Zeeuw D.; Wie, L.; Leslie, B.; List, J, Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013, 15, 853–862. [CrossRef] [PubMed]
61. Tanaka, T.; Nangaku, M, Recent advances and clinical application of erythropoietin and erythropoiesisstimulating agents. Exp. Cell Res. 2012, 318, 1068–1073. [CrossRef] [PubMed]
62. Sano, M.; Takei, M.; Shiraishi, Y.; Suzuki, Y, Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J. Clin. Med. Res. 2016, 8, 844–847. [CrossRef] [PubMed]
63. Eto, N.; Wada, T.; Inagi, R.; Takano, H.; Shimizu, A.; Kato, H.; Kurihara, H.; Kawachi, H.; Shankland, S.J.; Fujita, T.; et al. Podocyte protection by darbepoetin: Preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007, 72, 455–463. [CrossRef] [PubMed]
64. Aizawa, K.; Takeda, S.; Tashiro, Y.; Yorozu, K.; Hirata, M.; Kanada, H.; Moriguchi, Y.; Endo, K, Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am. J. Nephrol. 2012, 36, 419–426. [CrossRef] [PubMed]
65. Serizawa, K.; Yogo, K.; Tashiro, Y.; Aizawa, K.; Kawasaki, R.; Hirata, M.; Endo, K, Epoetin β pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats. Eur. J. Pharmacol. 2015, 767, 10–16. [CrossRef] [PubMed]
66. Eren, Z.; Gunal, M.Y.; Ari, E.; Coban, J.; Cakalagaoglu, F.; Caglayan, B.; Beker, M.C.; Akdeniz, T.; Yanikkaya, G.; Kilic, E.; et al. Pleiotropic and renoprotective effects of erythropoietin β on experimental diabetic nephropathy model. Nephron 2016, 132, 292–300. [CrossRef] [PubMed]
67. Tsuruya, K.; Yoshida, H.; Suehiro, T.; Fujisaki, K.; Masutani, K.; Kitazono, T, Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: A possibility of a direct action of erythropoietin. Ren. Fail. 2016, 38, 390–396. [CrossRef] [PubMed]
68. Koitka, A.; Tikellis, C, Advances in the renin-angiotensin-aldosterone system: Relevance to diabetic nephropathy. Sci. World J. 2008, 8, 434–445. [CrossRef] [PubMed]
69. Muskiet, M.H.; van Raalte, D.H.; van Bommel, E.J.; Smits, M.M.; Tonneijck, L, Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 2015, 3, 928–929. [CrossRef]
70. Padda, R.S.; Shi, Y.; Lo, C.S.; Zhang, S.L.; Chan, J.S, Angiotensin-(1–7): A Novel peptide to treat hypertension and nephropathy in diabetes? J. Diabetes Metab. 2015, 6. [CrossRef]
71. Prestes, T.R.; Rocha, N.P.; Miranda, A.S.; Teixeira, A.L.; Simoes-E-Silva, A.C, The anti-inflammatory potential of ACE2/Angiotensin-(1–7)/Mas receptor axis: Evidence from basic and clinical research. Curr. Drug Targets 2016. [CrossRef]
72. Shi, Y.; Lo, C.S.; Padda, R.; Abdo, S.; Chenier, I.; Filep, J.G.; Ingelfinger, J.R.; Zhang, S.L.; Chan, J.S, Angiotensin-(1–7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice, Clin. Sci. 2015, 128, 649–663. [CrossRef] [PubMed]
73. Bjornstad, P.; Lanaspa, M.A.; Ishimoto, T.; Kosugi, T.; Kume, S.; Jalal, D.; Maahs, D.M.; Snell-Bergeon, J.K.; Johnson, R.J.; Nakagawa, T, Fructose and uric acid in diabetic nephropathy. Diabetologia 2015, 58, 1993–2002. [CrossRef] [PubMed]
74. Jalal, D.I.; Maahs, D.M.; Hovind, P.; Nakagawa, T, Uric acid as a mediator of diabetic nephropathy. Semin. Nephrol. 2011, 31, 459–465. [CrossRef] [PubMed]
75. Lytvyn, Y.; Skrtic, M.; Yang, G.K.; Yip, P.M.; Perkins, B.A.; Cherney, D.Z, Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am. J. Physiol. Ren. Physiol. 2015, 308, F77–F83. [CrossRef] [PubMed]
76. Maahs, D.M.; Caramori, L.; Cherney, D.Z.; Galecki, A.T.; Gao, C.; Jalal, D.; Perkins, B.A.; Pop-Busui, R.; Rossing, P.; Mauer, M.; et al. Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study. Curr. Diab. Rep. 2013, 13, 550–559. [CrossRef] [PubMed]